Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Optimization of marine triterpene sipholenols as inhibitors of breast cancer migration and invasion.

Foudah AI, Jain S, Busnena BA, El Sayed KA.

ChemMedChem. 2013 Mar;8(3):497-510. doi: 10.1002/cmdc.201200516. Epub 2013 Feb 12.

PMID:
23404739
2.

Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.

Foudah AI, Sallam AA, Akl MR, El Sayed KA.

Eur J Med Chem. 2014 Feb 12;73:310-24. doi: 10.1016/j.ejmech.2013.11.039. Epub 2013 Dec 12.

PMID:
24487236
3.
4.

Sipholane triterpenoids: chemistry, reversal of ABCB1/P-glycoprotein-mediated multidrug resistance, and pharmacophore modeling.

Jain S, Abraham I, Carvalho P, Kuang YH, Shaala LA, Youssef DT, Avery MA, Chen ZS, El Sayed KA.

J Nat Prod. 2009 Jul;72(7):1291-8. doi: 10.1021/np900091y.

PMID:
19534474
5.

Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.

Shi Z, Jain S, Kim IW, Peng XX, Abraham I, Youssef DT, Fu LW, El Sayed K, Ambudkar SV, Chen ZS.

Cancer Sci. 2007 Sep;98(9):1373-80. Epub 2007 Jul 19.

6.

Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.

Abraham I, Jain S, Wu CP, Khanfar MA, Kuang Y, Dai CL, Shi Z, Chen X, Fu L, Ambudkar SV, El Sayed K, Chen ZS.

Biochem Pharmacol. 2010 Nov 15;80(10):1497-506. doi: 10.1016/j.bcp.2010.08.001. Epub 2010 Aug 7.

7.

Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids.

Jain S, Laphookhieo S, Shi Z, Fu LW, Akiyama S, Chen ZS, Youssef DT, van Soest RW, El Sayed KA.

J Nat Prod. 2007 Jun;70(6):928-31. Epub 2007 May 9.

PMID:
17488128
8.

Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance.

Zhang Y, Zhang YK, Wang YJ, Vispute SG, Jain S, Chen Y, Li J, Youssef DT, El Sayed KA, Chen ZS.

Mar Drugs. 2015 Apr 14;13(4):2267-86. doi: 10.3390/md13042267.

9.

Biocatalysis of the anticancer sipholane triterpenoids.

Jain S, Shirode A, Yacoub S, Barbo A, Sylvester PW, Huntimer E, Halaweish F, El Sayed KA.

Planta Med. 2007 Jun;73(6):591-6. Epub 2007 May 7.

PMID:
17486535
10.

PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.

Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH.

Breast Cancer Res Treat. 2011 Nov;130(1):85-96. doi: 10.1007/s10549-010-1302-4. Epub 2010 Dec 22.

PMID:
21181437
11.

Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer.

Busnena BA, Foudah AI, Melancon T, El Sayed KA.

Bioorg Med Chem. 2013 Apr 1;21(7):2117-27. doi: 10.1016/j.bmc.2012.12.050. Epub 2013 Jan 9.

PMID:
23403296
12.

Discovery, optimization, and pharmacophore modeling of oleanolic acid and analogues as breast cancer cell migration and invasion inhibitors through targeting Brk/Paxillin/Rac1 axis.

Elsayed HE, Akl MR, Ebrahim HY, Sallam AA, Haggag EG, Kamal AM, El Sayed KA.

Chem Biol Drug Des. 2015 Feb;85(2):231-43. doi: 10.1111/cbdd.12380. Epub 2014 Jul 16.

PMID:
24954090
13.

Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors.

Behery FA, Elnagar AY, Akl MR, Wali VB, Abuasal B, Kaddoumi A, Sylvester PW, El Sayed KA.

Bioorg Med Chem. 2010 Nov 15;18(22):8066-75. doi: 10.1016/j.bmc.2010.09.009. Epub 2010 Sep 19.

PMID:
20943398
14.

Marine natural products-inspired phenylmethylene hydantoins with potent in vitro and in vivo antitumor activities via suppression of Brk and FAK signaling.

Sallam AA, Mohyeldin MM, Foudah AI, Akl MR, Nazzal S, Meyer SA, Liu YY, El Sayed KA.

Org Biomol Chem. 2014 Jul 28;12(28):5295-303. doi: 10.1039/c4ob00553h.

PMID:
24927150
15.

Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.

Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL, Schwertfeger KL, Lange CA.

Breast Cancer Res. 2011 Sep 17;13(5):R89. doi: 10.1186/bcr2946.

16.

Semisynthetic analogues of the marine cembranoid sarcophine as prostate and breast cancer migration inhibitors.

Hassan HM, Sallam AA, Mohammed R, Hifnawy MS, Youssef DT, El Sayed KA.

Bioorg Med Chem. 2011 Aug 15;19(16):4928-34. doi: 10.1016/j.bmc.2011.06.060. Epub 2011 Jun 28.

PMID:
21775154
17.

Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.

Ludyga N, Anastasov N, Gonzalez-Vasconcellos I, Ram M, Höfler H, Aubele M.

Mol Biosyst. 2011 May;7(5):1603-12. doi: 10.1039/c0mb00286k. Epub 2011 Mar 4.

PMID:
21380407
18.

Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells.

Wang KL, Hsia SM, Chan CJ, Chang FY, Huang CY, Bau DT, Wang PS.

Expert Opin Ther Targets. 2013 Apr;17(4):337-49. doi: 10.1517/14728222.2013.756869. Epub 2013 Jan 18.

PMID:
23327692
19.

Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.

Zuo Y, Wu Y, Chakraborty C.

J Cell Physiol. 2012 Apr;227(4):1399-407. doi: 10.1002/jcp.22853.

PMID:
21618528
20.

Frondoside A inhibits human breast cancer cell survival, migration, invasion and the growth of breast tumor xenografts.

Al Marzouqi N, Iratni R, Nemmar A, Arafat K, Ahmed Al Sultan M, Yasin J, Collin P, Mester J, Adrian TE, Attoub S.

Eur J Pharmacol. 2011 Oct 1;668(1-2):25-34. doi: 10.1016/j.ejphar.2011.06.023. Epub 2011 Jun 27.

PMID:
21741966

Supplemental Content

Support Center